Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come
Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy, Ozempic, and Rybelsus), owned by Novo Nordisk; and tirzepatide (Zepbound, Mounjaro), owned by Eli Lilly. All five of those drug brands, with the exception of Rybelsus, are administered by injection, whereas Rybelsus is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and Wegovy was also approved by the FDA in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more
正在研究西瑪魯肽在心臟病、阿爾茨海默氏症、肝病等方面的應用
GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come
GLP-1 藥物預計將在未來幾年產生數千億美元的收入
KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following strategic update.
不列顛哥倫比亞省基洛納/ACCESSWIRE/2024年11月26日/藥物遞送平台領域的全球創新者Lexaria Bioscience Corp.（納斯達克股票代碼：LEXXW）（「公司」 或 「Lexaria」）提供了以下戰略最新情況。
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy, Ozempic, and Rybelsus), owned by Novo Nordisk; and tirzepatide (Zepbound, Mounjaro), owned by Eli Lilly. All five of those drug brands, with the exception of Rybelsus, are administered by injection, whereas Rybelsus is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and Wegovy was also approved by the FDA in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.
當今的 GLP-1 藥物市場主要由諾和諾德旗下的索馬魯肽（Wegovy、Ozempic和Rybelsus）和禮來公司旗下的替塞帕肽（Zepbound、Mounjaro）組成。除Rybelsus外，所有五個藥物品牌均通過注射給藥，而Rybelsus是當今唯一獲得美國食品藥品管理局批准的口服片劑。雖然這兩種藥物最初由美國食品藥品管理局批准用於糖尿病管理，但很快就獲得了減肥批准，Wegovy也於2024年3月獲得美國食品藥品管理局的批准，以降低心血管死亡、心臟病發作和中風的風險。
Acceptance and use of these two drugs by the public has resulted in unprecedented demand, with estimates of 2024 revenue between them of ~$30 billion, compared to just $300 million in 2018, an increase of 100x or 10,000%.
公衆對這兩種藥物的接受和使用帶來了前所未有的需求，據估計，2024年，它們之間的收入約爲300億美元，而2018年僅爲3億美元，增長了100倍，增長了10,000％。
